Entrar/Registro  
INICIO ENGLISH
 
Revista de Investigación Clínica
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Revista de Investigación Clínica >Año 2013, No. 2


Torres-Jasso JH, Bustos-Carpinteyro AR, Marín ME, Santiago E, Leoner C, Flores-Luna L, Torres J, Sánchez-Lopez JY
Análisis de los polimorfismos EGFR-R521K y ERBB2-I655V en pacientes mexicanos con cáncer gástrico y lesiones gástricas premalignas
Rev Invest Clin 2013; 65 (2)

Idioma: Inglés
Referencias bibliográficas: 32
Paginas: 150-155
Archivo PDF: 152.18 Kb.


Texto completo




RESUMEN

Los proto-oncogenes epidermal growth factor receptor (EGFR) y erythroblastic leukemia viral oncogene homolog 2 (ERBB2), se encuentran involucrados en el desarrollo de diversos tumores malignos, incluyendo cáncer gástrico. En este trabajo se analiza la asociación de los SNPs EGFRR521K y ERBB2-I655V con cáncer gástrico y lesiones gástricas premalignas en pacientes mexicanos. Mediante análisis de polimorfismos en la longitud de fragmentos de restricción, se analizaron ambos SNPs en el ADN de 155 pacientes con cáncer gástrico y lesiones gástricas premalignas, 121 controles, y 103 sujetos de población general. Las frecuencias de ambos SNPs no difirieron significativamente entre los grupos (χ2 p = NS); el análisis de razón de momios mostró que los alelos EGFR-521K y ERBB2-655V no están relacionados con cáncer gástrico o lesiones gástricas premalignas en la población mexicana. Los datos sugieren que los polimorfismos EGFRR521K y ERBB2-I655V no pueden considerarse como marcadores útiles en la identificación de sujetos con riesgo de desarrollar cáncer gástrico en nuestra población.


Palabras clave: Cáncer gástrico, Gastritis, Metaplasia intestinal, EGFR, HER-2.


REFERENCIAS

  1. Garcia M, Jemal A, Ward EM, Center MM, et al. Global Cancer Facts & Figures. American Cancer Society. Atlanta, GA. 2007.

  2. Boyle P, Levin B. Cancer by Site: Stomach Cancer. World Cancer Report 2008. WHO Press; 2008, p. 344-9.

  3. IARC. International Agency for Research in Cancer. GLOBOCAN 2008: Country Fast Stat. Available from: http:// globocan.iarc.fr/factsheet.asp.

  4. Kharrat N, Al’Fadhli S, Rebai A. Screening and Validation of Dinucleotide Repeats in Intron 1 of the Human EGFR Gene and its Paralog in the HER2 Gene. J Recept Signal Transduct Res 2008; 28(5): 475-83.

  5. Wang K, Yamamoto H, Chin JR, Werb Z, et al. Epidermal growth factor receptor-deficient mice have delayed primary endochondral ossification because of defective osteoclast recruitment. J Biol Chem 2004; 279(51): 53848-56.

  6. Kruszyna L, Lianeri M, Roszak A, Jagodziñski PP. HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma. Clin Biochem 2010; 43(6): 545-8.

  7. Murray S, Dahabreh IJ, Linardou H, Manoloukos M, et al. Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. J Thorac Oncol 2008; 3(8): 832-9.

  8. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37(S4): 9-15.

  9. Ameyaw MM, Tayeb M, Thornton N, Folayan G, et al. Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer. J Hum Genet 2002; 47(4): 172-5.

  10. Ménard S, Casalini P, Campiglio M, Pupa S, et al. HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Ann Oncol 2001; 12(S1): 15-9.

  11. Martinelli M, Ugolini G, Scapoli L, Rivetti S, et al. The EGFR R521K polymorphism influences the risk to develop colorectal cancer. Cancer Biomark 2011; 8(2): 61-5.

  12. Wang WS, Chen PM, Chiou TJ, Liu JH, et al. Epidermal Growth Factor Receptor R497K Polymorphism Is a Favorable Prognostic Factor for Patients with Colorectal Carcinoma. Clin Cancer Res 2007; 13(12): 3597-604.

  13. Montgomery KG, Gertig DM, Baxter SW, Milne RL, et al. The HER2 I655V polymorphism and risk of breast cancer in women < age 40 years. Cancer Epidemiol Biomarkers Prev 2003; 12(10): 1109-11.

  14. Benusiglio PR, Lesueur F, Luccarini C, Conroy DM, et al. Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study. Breast Cancer Res 2005; 7(2): R204-R209.

  15. Kuraoka K, Matsumura S, Hamai Y, Nakachi K, et al. A single nucleotide polymorphism in the transmembrane domain coding region of HER-2 is associated with development and malignant phenotype of gastric cancer. Int J Cancer 2003; 107(4): 593-6.

  16. Satiroglu-Tufan NL, Bir F, Calli-Demirkan N. Investigation of HER-2 codon 655 single nucleotide polymorphism frequency and c-ErbB-2 protein expression alterations in gastric cancer patients. World J Gastroenterol 2006; 12(20): 3283-7.

  17. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16(3): 1215.

  18. Zhang W, Park DJ, Lu B, Yang DY, et al. Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. Clin Cancer Res 2005; 11(2): 600-5.

  19. Sanguinetti CJ, Dias Neto E, Simpson AJ. Rapid silver staining and recovery of PCR products separated on polyacrylamide gels. Biotechniques 1994; 17(5): 914-21.

  20. Database of Single Nucleotide Polymorphisms (dbSNP). National Center for Biotechnology Information, National Library of Medicine. dbSNP accession: (dbSNP Build ID: {EGFR (1956)}). Available from: http://www.ncbi.nlm.nih.gov/projects/ SNP/snp_ref.cgi?rs=2227983.

  21. ALFRED. The Allele Frequency Database. Available from: http://alfred.med.yale.edu/.

  22. Database of Single Nucleotide Polymorphisms (dbSNP). National Center for Biotechnology Information, National Library of Medicine. (dbSNP Build ID: {ERBB2 (2064)}). Available from: http://www.ncbi.nlm.nih.gov/projects/SNP/ snp_ref.cgi?rs=1136201.

  23. Salazar-Flores J, Dondiego-Aldape R, Rubi-Castellanos R, Anaya- Palafox M, et al. Population structure and paternal admixture landscape on present-day Mexican-Mestizos revealed by Y-STR haplotypes. Am J Hum Biol 2010; 22(3): 401-9.

  24. Gorodezky C, Alaez C, Vázquez-García MN, de la Rosa G, et al. The genetic structure of Mexican Mestizos of different locations: tracking back their origins through MHC genes, blood group systems, and microsatellites. Hum Immunol 2001; 62(9): 979-91.

  25. Martínez-Cortés G, Salazar-Flores J, Fernández-Rodríguez LG, Rubi-Castellanos R, et al. Admixture and population structure in Mexican-Mestizos based on paternal lineages. J Hum Genet 2012; 57(9): 568-74.

  26. Lindblad M, Ye W, Rubio C, Lagergren J. Estrogen and risk of gastric cancer: a protective effect in a nationwide cohort study of patients with prostate cancer in Sweden. Cancer Epidemiol Biomarkers Prev 2004; 13(12): 2203-7.

  27. Ohtani M, García A, Rogers AB, Ge Z, et al. Protective role of 17b-estradiol against the development of Helicobacter pyloriinduced gastric cancer in INS-GAS mice. Carcinogenesis 2007; 28(12): 2597-604.

  28. Pandey R, Misra V, Misra SP, Dwivedi M, et al. Helicobacter pylori and gastric cancer. Asian Pac J Cancer Prev 2010; 11(3): 583-8.

  29. Correa P. Human Gastric Carcinogenesis: A Multistep and Multifactorial Process-First American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res 1992; 52: 6735-40.

  30. Moriai T, Kobrin MS, Hope C, Speck L, et al. A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling. Proc Natl Acad Sci USA 1994; 91(21): 10217-21.

  31. Fleishman SJ, Schlessinger J, Ben-Tal N. A putative molecularactivation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci USA 2002; 99(25): 15937-40.

  32. Frank B, Hemminki K, Wirtenberger M, Bermejo JL, et al. The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. Carcinogenesis 2005; 26(3): 643-7.



>Revistas >Revista de Investigación Clínica >Año2013, No. 2
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019